Dementia Prevention in Clinical Practice

Abstract

Over 55 million people globally are living with dementia and, by 2050, this number is projected to increase to 131 million. This poses immeasurable challenges for patients and their families and a significant threat to domestic and global economies. Given this public health crisis and disappointing results from disease-modifying trials, there has been a recent shift in focus toward primary and secondary prevention strategies. Approximately 40% of Alzheimer's disease (AD) cases, which is the most common form of dementia, may be prevented or at least delayed. Success of risk reduction studies through addressing modifiable risk factors, in addition to the failure of most drug trials, lends support for personalized multidomain interventions rather than a “one-size-fits-all” approach. Evolving evidence supports early intervention in at-risk patients using individualized interventions directed at modifiable risk factors. Comprehensive risk stratification can be informed by emerging principals of precision medicine, and include expanded clinical and family history, anthropometric measurements, blood biomarkers, neurocognitive evaluation, and genetic information. Risk stratification is key in differentiating subtypes of dementia and identifies targetable areas for intervention. This article reviews a clinical approach toward dementia risk stratification and evidence-based prevention strategies, with a primary focus on AD.

Keywords

Alzheimer's disease prevention - dementia prevention - precision medicine

Publication History

Article published online:
28 November 2022

• References

• 1 Chin JH, Vora N. The global burden of neurologic diseases. Neurology 2014; 83 (04) 349-351
• 2 Arvanitakis Z, Shah RC, Bennett DA. Diagnosis and management of dementia: review. JAMA 2019; 322 (16) 1589-1599
• 3 Dementia [online]. Accessed November 14, 2022 at: https://www.who.int/news-room/fact-sheets/detail/dementia
• 4 Hurd MD, Martorell P, Delavande A, Mullen KJ, Langa KM. Monetary costs of dementia in the United States. N Engl J Med 2013; 368 (14) 1326-1334
• 5 Wimo A, Jönsson L, Bond J, Prince M, Winblad B, International AD. Alzheimer Disease International. The worldwide economic impact of dementia 2010. Alzheimers Dement 2013; 9 (01) 1-11.e3
• 6 Wimo A, Guerchet M, Ali G-C. et al. The worldwide costs of dementia 2015 and comparisons with 2010. Alzheimers Dement 2017; 13 (01) 1-7
• 7 Sosa-Ortiz AL, Acosta-Castillo I, Prince MJ. Epidemiology of dementias and Alzheimer's disease. Arch Med Res 2012; 43 (08) 600-608
• 8 Zucchella C, Sinforiani E, Tamburin S. et al. The multidisciplinary approach to Alzheimer's disease and dementia. A narrative review of non-pharmacological treatment. Front Neurol 2018; 9: 1058
• 9 Cummings J. New approaches to symptomatic treatments for Alzheimer's disease. Mol Neurodegener 2021; 16 (01) 2
• 10 World Health Organization. Risk Reduction of Cognitive Decline and Dementia: WHO Guidelines. 2019
• 11 Livingston G, Huntley J, Sommerlad A. et al. Dementia prevention, intervention, and care: 2020 report of the Lancet Commission. Lancet 2020; 396 (10248): 413-446
• 12 Brookmeyer R, Johnson E, Ziegler-Graham K, Arrighi HM. Forecasting the global burden of Alzheimer's disease. Alzheimers Dement 2007; 3 (03) 186-191
• 13 Zissimopoulos J, Crimmins E, St Clair P. The value of delaying Alzheimer's disease onset. Forum Health Econ Policy 2014; 18 (01) 25-39
• 14 World Health Organization. Global Action Plan on the Public Health Response to Dementia 2017–2025. 2017
• 15 2021 Alzheimer's disease facts and figures. Alzheimers Dement 2021; 17 (03) 327-406
• 16 Risacher SL, Anderson WH, Charil A. et al; Alzheimer's Disease Neuroimaging Initiative. Alzheimer disease brain atrophy subtypes are associated with cognition and rate of decline. Neurology 2017; 89 (21) 2176-2186
• 17 Ossenkoppele R, Schonhaut DR, Schöll M. et al. Tau PET patterns mirror clinical and neuroanatomical variability in Alzheimer's disease. Brain 2016; 139 (Pt 5): 1551-1567
• 18 Vogel JW, Young AL, Oxtoby NP. et al; Alzheimer's Disease Neuroimaging Initiative. Four distinct trajectories of tau deposition identified in Alzheimer's disease. Nat Med 2021; 27 (05) 871-881
• 19 Ferreira D, Nordberg A, Westman E. Biological subtypes of Alzheimer disease: a systematic review and meta-analysis. Neurology 2020; 94 (10) 436-448
• 20 Seifan A, Isaacson R. The Alzheimer's Prevention Clinic at Weill Cornell Medical College/New York - Presbyterian Hospital: Risk Stratification and Personalized Early Intervention. J Prev Alzheimers Dis 2015; 2 (04) 254-266
• 21 Isaacson RS, Ganzer CA, Hristov H. et al. The clinical practice of risk reduction for Alzheimer's disease: a precision medicine approach. Alzheimers Dement 2018; 14 (12) 1663-1673
• 22 Duong S, Patel T, Chang F. Dementia: what pharmacists need to know. Can Pharm J 2017; 150 (02) 118-129
• 23 Nelson PT, Jicha GA, Kryscio RJ. et al. Low sensitivity in clinical diagnoses of dementia with Lewy bodies. J Neurol 2010; 257 (03) 359-366
• 24 Lindau M, Almkvist O, Kushi J. et al. First symptoms–frontotemporal dementia versus Alzheimer's disease. Dement Geriatr Cogn Disord 2000; 11 (05) 286-293
• 25 Devenney EM, Ahmed RM, Halliday G, Piguet O, Kiernan MC, Hodges JR. Psychiatric disorders in C9orf72 kindreds: study of 1,414 family members. Neurology 2018; 91 (16) e1498-e1507
• 26 Boeve BF, Silber MH, Ferman TJ, Lucas JA, Parisi JE. Association of REM sleep behavior disorder and neurodegenerative disease may reflect an underlying synucleinopathy. Mov Disord 2001; 16 (04) 622-630
• 27 Walker IM, Fullard ME, Morley JF, Duda JE. Olfaction as an early marker of Parkinson's disease and Alzheimer's disease. In: Swaab DF, Buijs RM, Kreier F, Lucassen PJ, Salehi A. eds. Handbook of Clinical Neurology. Elsevier; 2021: 317-329
• 28 Hsu F-C, Yuan M, Bowden DW. et al. Adiposity is inversely associated with hippocampal volume in African Americans and European Americans with diabetes. J Diabetes Complications 2016; 30 (08) 1506-1512
• 29 Power MC, Rawlings A, Sharrett AR. et al. Association of midlife lipids with 20-year cognitive change: a cohort study. Alzheimers Dement 2018; 14 (02) 167-177
• 30 Sniderman A, Langlois M, Cobbaert C. Update on apolipoprotein B. Curr Opin Lipidol 2021; 32 (04) 226-230
• 31 Pencina MJ, Pencina KM, Lloyd-Jones D, Catapano AL, Thanassoulis G, Sniderman AD. The expected 30-year benefits of early versus delayed primary prevention of cardiovascular disease by lipid lowering. Circulation 2020; 142 (09) 827-837
• 32 Slot RER, Van Harten AC, Kester MI. et al. Apolipoprotein A1 in cerebrospinal fluid and plasma and progression to Alzheimer's disease in non-demented elderly. J Alzheimers Dis 2017; 56 (02) 687-697
• 33 Mirza SS, de Bruijn RF, Koudstaal PJ. et al. The N-terminal pro B-type natriuretic peptide, and risk of dementia and cognitive decline: a 10-year follow-up study in the general population. J Neurol Neurosurg Psychiatry 2016; 87 (04) 356-362
• 34 de Nazareth AM. Type 2 diabetes mellitus in the pathophysiology of Alzheimer's disease. Dement Neuropsychol 2017; 11 (02) 105-113
• 35 Takeda S, Sato N, Uchio-Yamada K. et al. Diabetes-accelerated memory dysfunction via cerebrovascular inflammation and Abeta deposition in an Alzheimer mouse model with diabetes. Proc Natl Acad Sci U S A 2010; 107 (15) 7036-7041
• 36 Hackett K, Krikorian R, Giovannetti T. et al. Utility of the NIH Toolbox for assessment of prodromal Alzheimer's disease and dementia. Alzheimers Dement (Amst) 2018; 10: 764-772
• 37 Papp KV, Rentz DM, Orlovsky I, Sperling RA, Mormino EC. Optimizing the preclinical Alzheimer's cognitive composite with semantic processing: The PACC5. Alzheimers Dement (N Y) 2017; 3 (04) 668-677
• 38 Langbaum JB, Ellison NN, Caputo A. et al. The Alzheimer's Prevention Initiative Composite Cognitive Test: a practical measure for tracking cognitive decline in preclinical Alzheimer's disease. Alzheimers Res Ther 2020; 12 (01) 66
• 39 Mollenhauer B, Förstl H, Deuschl G, Storch A, Oertel W, Trenkwalder C. Lewy body and parkinsonian dementia: common, but often misdiagnosed conditions. Dtsch Arztebl Int 2010; 107 (39) 684-691
• 40 Silverberg NB, Ryan LM, Carrillo MC. et al. Assessment of cognition in early dementia. Alzheimers Dement 2011; 7 (03) e60-e76
• 41 Saunders AM, Trowers MK, Shimkets RA. et al. The role of apolipoprotein E in Alzheimer's disease: pharmacogenomic target selection. Biochim Biophys Acta 2000; 1502 (01) 85-94
• 42 Is Alzheimer's Genetic? [online]. Accessed November 14, 2022 at: https://www.alz.org/alzheimers-dementia/what-is-alzheimers/causes-and-risk-factors/genetics
• 43 Wu L, Zhao L. ApoE2 and Alzheimer's disease: time to take a closer look. Neural Regen Res 2016; 11 (03) 412-413
• 44 Scheltens P, De Strooper B, Kivipelto M. et al. Alzheimer's disease. Lancet 2021; 397 (10284): 1577-1590
• 45 Emrani S, Arain HA, DeMarshall C, Nuriel T. APOE4 is associated with cognitive and pathological heterogeneity in patients with Alzheimer's disease: a systematic review. Alzheimers Res Ther 2020; 12 (01) 141
• 46 Carrieri G, Bonafè M, De Luca M. et al. Mitochondrial DNA haplogroups and APOE4 allele are non-independent variables in sporadic Alzheimer's disease. Hum Genet 2001; 108 (03) 194-198
• 47 Erickson CM, Schultz SA, Oh JM. et al. KLOTHO heterozygosity attenuates APOE4-related amyloid burden in preclinical AD. Neurology 2019; 92 (16) e1878-e1889
• 48 Wang Y, Brinton RD. Triad of risk for late onset Alzheimer's: mitochondrial haplotype, APOE genotype and chromosomal sex. Front Aging Neurosci 2016; 8: 232
• 49 Belloy ME, Napolioni V, Han SS, Le Guen Y, Greicius MD. Alzheimer's Disease Neuroimaging Initiative. Association of klotho-VS heterozygosity with risk of Alzheimer disease in individuals who carry APOE4. JAMA Neurol 2020; 77 (07) 849-862
• 50 Dubal DB, Yokoyama JS. Longevity gene KLOTHO and Alzheimer disease - a better fate for individuals who carry APOE ε4. JAMA Neurol 2020; 77 (07) 798-800
• 51 Dubal DB, Yokoyama JS, Zhu L. et al. Life extension factor klotho enhances cognition. Cell Rep 2014; 7 (04) 1065-1076
• 52 Neitzel J, Franzmeier N, Rubinski A. et al; Alzheimer's Disease Neuroimaging Initiative (ADNI). KL-VS heterozygosity is associated with lower amyloid-dependent tau accumulation and memory impairment in Alzheimer's disease. Nat Commun 2021; 12 (01) 3825
• 53 Symposia—Oral Communications—Late Breaking News. J Prev Alzheimers Dis 2021; 8: S1-S72
• 54 Blumenthal JA, Smith PJ, Mabe S. et al. Lifestyle and neurocognition in older adults with cognitive impairments: a randomized trial. Neurology 2019; 92 (03) e212-e223
• 55 Isaacson RS, Hristov H, Saif N. et al. Individualized clinical management of patients at risk for Alzheimer's dementia. Alzheimers Dement 2019; 15 (12) 1588-1602
• 56 Richard E, Van den Heuvel E, Moll van Charante EP. et al. Prevention of dementia by intensive vascular care (PreDIVA): a cluster-randomized trial in progress. Alzheimer Dis Assoc Disord 2009; 23 (03) 198-204
• 57 Vellas B, Carrie I, Gillette-Guyonnet S. et al. MAPT Study: a multidomain approach for preventing Alzheimer's disease: design and baseline data. J Prev Alzheimers Dis 2014; 1 (01) 13-22
• 58 Sink KM, Espeland MA, Castro CM. et al; LIFE Study Investigators. Effect of a 24-month physical activity intervention vs health education on cognitive outcomes in sedentary older adults: the LIFE randomized trial. JAMA 2015; 314 (08) 781-790
• 59 Schelke MW, Attia P, Palenchar DJ. et al. Mechanisms of risk reduction in the clinical practice of Alzheimer's disease prevention. Front Aging Neurosci 2018; 10: 96-96
• 60 Han J-Y, Han S-H. Primary prevention of Alzheimer's disease: is it an attainable goal?. J Korean Med Sci 2014; 29 (07) 886-892
• 61 Vincent GK, Velkoff VA. The Next Four Decades: The Older Population in the United States: 2010 to 2050. USCB; 2010
• 62 Salat DH, Kaye JA, Janowsky JS. Prefrontal gray and white matter volumes in healthy aging and Alzheimer disease. Arch Neurol 1999; 56 (03) 338-344
• 63 Murman DL. The impact of age on cognition. Semin Hear 2015; 36 (03) 111-121
• 64 Hou Y, Dan X, Babbar M. et al. Ageing as a risk factor for neurodegenerative disease. Nat Rev Neurol 2019; 15 (10) 565-581
• 65 Xia X, Jiang Q, McDermott J, Han JJ. Aging and Alzheimer's disease: comparison and associations from molecular to system level. Aging Cell 2018; 17 (05) e12802-e12802
• 66 Krstic D, Madhusudan A, Doehner J. et al. Systemic immune challenges trigger and drive Alzheimer-like neuropathology in mice. J Neuroinflammation 2012; 9: 151-151
• 67 Charisis S, Ntanasi E, Yannakoulia M. et al. Diet inflammatory index and dementia incidence: a population-based study. Neurology 2021; 97 (24) e2381-e2391
• 68 Andrew MK, Tierney MC. The puzzle of sex, gender and Alzheimer's disease: Why are women more often affected than men?. Womens Health (Lond) 2018; 14: 1745506518817995
• 69 Brookmeyer R, Gray S, Kawas C. Projections of Alzheimer's disease in the United States and the public health impact of delaying disease onset. Am J Public Health 1998; 88 (09) 1337-1342
• 70 Viña J, Lloret A. Why women have more Alzheimer's disease than men: gender and mitochondrial toxicity of amyloid-β peptide. J Alzheimers Dis 2010; 20 (Suppl. 02) S527-S533
• 71 Carter CL, Resnick EM, Mallampalli M, Kalbarczyk A. Sex and gender differences in Alzheimer's disease: recommendations for future research. J Womens Health (Larchmt) 2012; 21 (10) 1018-1023
• 72 Rahman A, Jackson H, Hristov H. et al. Sex and gender driven modifiers of Alzheimer's: the role for estrogenic control across age, race, medical, and lifestyle risks. Front Aging Neurosci 2019; 11: 315
• 73 Scheyer O, Rahman A, Hristov H. et al. Female sex and Alzheimer's risk: the menopause connection. J Prev Alzheimers Dis 2018; 5 (04) 225-230
• 74 Mosconi L, Rahman A, Diaz I. et al. Increased Alzheimer's risk during the menopause transition: a 3-year longitudinal brain imaging study. PLoS One 2018; 13 (12) e0207885
• 75 Maki PM. Critical window hypothesis of hormone therapy and cognition: a scientific update on clinical studies. Menopause 2013; 20 (06) 695-709
• 76 Brinton RD. Impact of estrogen therapy on Alzheimer's disease: a fork in the road?. CNS Drugs 2004; 18 (07) 405-422
• 77 Vinogradova Y, Dening T, Hippisley-Cox J, Taylor L, Moore M, Coupland C. Use of menopausal hormone therapy and risk of dementia: nested case-control studies using QResearch and CPRD databases. BMJ 2021; 374 (2182): n2182
• 78 Shumaker SA, Legault C, Kuller L. et al; Women's Health Initiative Memory Study. Conjugated equine estrogens and incidence of probable dementia and mild cognitive impairment in postmenopausal women: Women's Health Initiative Memory Study. JAMA 2004; 291 (24) 2947-2958
• 79 Shumaker SA, Legault C, Rapp SR. et al; WHIMS Investigators. Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial. JAMA 2003; 289 (20) 2651-2662
• 80 Henderson VW, St John JA, Hodis HN. et al. Cognitive effects of estradiol after menopause: a randomized trial of the timing hypothesis. Neurology 2016; 87 (07) 699-708
• 81 Song YJ, Li SR, Li XW. et al. The effect of estrogen replacement therapy on Alzheimer's disease and Parkinson's disease in postmenopausal women: a meta-analysis. Front Neurosci 2020; 14: 157
• 82 Zandi PP, Carlson MC, Plassman BL. et al; Cache County Memory Study Investigators. Hormone replacement therapy and incidence of Alzheimer disease in older women: the Cache County Study. JAMA 2002; 288 (17) 2123-2129
• 83 Kantarci K, Lowe VJ, Lesnick TG. et al. Early postmenopausal transdermal 17β-estradiol therapy and amyloid-β deposition. J Alzheimers Dis 2016; 53 (02) 547-556
• 84 LeBlanc ES, Janowsky J, Chan BK, Nelson HD. Hormone replacement therapy and cognition: systematic review and meta-analysis. JAMA 2001; 285 (11) 1489-1499
• 85 Blacher J, Kretz S, Sorbets E, Lelong H, Vallée A, Lopez-Sublet M. [Epidemiology of hypertension: differences between women and men]. Presse Med 2019; 48 (11, Pt 1): 1240-1243
• 86 Hayden KM, Zandi PP, Lyketsos CG. et al; Cache County Investigators. Vascular risk factors for incident Alzheimer disease and vascular dementia: the Cache County study. Alzheimer Dis Assoc Disord 2006; 20 (02) 93-100
• 87 Baker LD, Frank LL, Foster-Schubert K. et al. Effects of aerobic exercise on mild cognitive impairment: a controlled trial. Arch Neurol 2010; 67 (01) 71-79
• 88 Hörder H, Johansson L, Guo X. et al. Midlife cardiovascular fitness and dementia: a 44-year longitudinal population study in women. Neurology 2018; 90 (15) e1298-e1305
• 89 Fallah N, Mitnitski A, Middleton L, Rockwood K. Modeling the impact of sex on how exercise is associated with cognitive changes and death in older Canadians. Neuroepidemiology 2009; 33 (01) 47-54
• 90 Eggermont L, Swaab D, Luiten P, Scherder E. Exercise, cognition and Alzheimer's disease: more is not necessarily better. Neurosci Biobehav Rev 2006; 30 (04) 562-575
• 91 Kwak YS, Um SY, Son TG, Kim DJ. Effect of regular exercise on senile dementia patients. Int J Sports Med 2008; 29 (06) 471-474
• 92 Liu-Ambrose T, Nagamatsu LS, Graf P, Beattie BL, Ashe MC, Handy TC. Resistance training and executive functions: a 12-month randomized controlled trial. Arch Intern Med 2010; 170 (02) 170-178
• 93 Cassilhas RC, Viana VA, Grassmann V. et al. The impact of resistance exercise on the cognitive function of the elderly. Med Sci Sports Exerc 2007; 39 (08) 1401-1407
• 94 Best JR, Chiu BK, Liang Hsu C, Nagamatsu LS, Liu-Ambrose T. Long-term effects of resistance exercise training on cognition and brain volume in older women: results from a randomized controlled trial. J Int Neuropsychol Soc 2015; 21 (10) 745-756
• 95 Weuve J, Kang JH, Manson JE, Breteler MM, Ware JH, Grodstein F. Physical activity, including walking, and cognitive function in older women. JAMA 2004; 292 (12) 1454-1461
• 96 Letenneur L, Launer LJ, Andersen K. et al; EURODEM Incidence Research Group. Education and the risk for Alzheimer's disease: sex makes a difference. EURODEM pooled analyses. Am J Epidemiol 2000; 151 (11) 1064-1071
• 97 Flicker L, Almeida OP, Acres J. et al. Predictors of impaired cognitive function in men over the age of 80 years: results from the Health in Men Study. Age Ageing 2005; 34 (01) 77-80
• 98 Olatunji BO, Kauffman BY, Meltzer S, Davis ML, Smits JA, Powers MB. Cognitive-behavioral therapy for hypochondriasis/health anxiety: a meta-analysis of treatment outcome and moderators. Behav Res Ther 2014; 58: 65-74
• 99 Ihle A, Oris M, Fagot D, Baeriswyl M, Guichard E, Kliegel M. The association of leisure activities in middle adulthood with cognitive performance in old age: the moderating role of educational level. Gerontology 2015; 61 (06) 543-550
• 100 Borenstein AR, Copenhaver CI, Mortimer JA. Early-life risk factors for Alzheimer disease. Alzheimer Dis Assoc Disord 2006; 20 (01) 63-72
• 101 Wilson RS, Begeny CT, Boyle PA, Schneider JA, Bennett DA. Vulnerability to stress, anxiety, and development of dementia in old age. Am J Geriatr Psychiatry 2011; 19 (04) 327-334
• 102 Peavy GM, Lange KL, Salmon DP. et al. The effects of prolonged stress and APOE genotype on memory and cortisol in older adults. Biol Psychiatry 2007; 62 (05) 472-478
• 103 Bromberger JT, Kravitz HM, Chang YF, Cyranowski JM, Brown C, Matthews KA. Major depression during and after the menopausal transition: Study of Women's Health Across the Nation (SWAN). Psychol Med 2011; 41 (09) 1879-1888
• 104 Szoeke CE, Robertson JS, Rowe CC. et al. The Women's Healthy Ageing Project: fertile ground for investigation of healthy participants 'at risk' for dementia. Int Rev Psychiatry 2013; 25 (06) 726-737
• 105 Khalsa DS. Stress, meditation, and Alzheimer's disease prevention: where the evidence stands. J Alzheimers Dis 2015; 48 (01) 1-12
• 106 Khalsa DS, Newberg AB. Spiritual fitness: a new dimension in Alzheimer's disease prevention. J Alzheimers Dis 2021; 80 (02) 505-519
• 107 Salmoirago-Blotcher E, Trivedi D, Dunsiger S. et al. Exploring effects of aerobic exercise and mindfulness training on cognitive function in older adults at risk of dementia: a feasibility, proof-of-concept study. Am J Alzheimers Dis Other Demen 2021;36:15333175211039094
• 108 Ng TKS, Fam J, Feng L. et al. Mindfulness improves inflammatory biomarker levels in older adults with mild cognitive impairment: a randomized controlled trial. Transl Psychiatry 2020; 10 (01) 21-21
• 109 Innes KE, Selfe TK. Meditation as a therapeutic intervention for adults at risk for Alzheimer's disease - potential benefits and underlying mechanisms. Front Psychiatry 2014; 5: 40-40
• 110 Epel ES, Puterman E, Lin J. et al. Meditation and vacation effects have an impact on disease-associated molecular phenotypes. Transl Psychiatry 2016; 6 (08) e880
• 111 Reid LD, Avens FE, Walf AA. Cognitive behavioral therapy (CBT) for preventing Alzheimer's disease. Behav Brain Res 2017; 334: 163-177
• 112 Wegner M, Helmich I, Machado S, Nardi AE, Arias-Carrion O, Budde H. Effects of exercise on anxiety and depression disorders: review of meta- analyses and neurobiological mechanisms. CNS Neurol Disord Drug Targets 2014; 13 (06) 1002-1014
• 113 Hoge EA, Chen MM, Orr E. et al. Loving-Kindness Meditation practice associated with longer telomeres in women. Brain Behav Immun 2013; 32: 159-163
• 114 Saif N, Hristov H, Akiyoshi K. et al. Sex-driven differences in the effectiveness of individualized clinical management of Alzheimer's disease risk. J Prev Alzheimers Dis 2022; 9 (04) 731-742
• 115 Bateman RJ, Aisen PS, De Strooper B. et al. Autosomal-dominant Alzheimer's disease: a review and proposal for the prevention of Alzheimer's disease. Alzheimers Res Ther 2011; 3 (01) 1
• 116 Cruts M, Van Broeckhoven C. Presenilin mutations in Alzheimer's disease. Hum Mutat 1998; 11 (03) 183-190
• 117 St George-Hyslop PH, Haines JL, Farrer LA. et al; FAD Collaborative Study Group. Genetic linkage studies suggest that Alzheimer's disease is not a single homogeneous disorder. Nature 1990; 347 (6289): 194-197
• 118 Winblad B, Amouyel P, Andrieu S. et al. Defeating Alzheimer's disease and other dementias: a priority for European science and society. Lancet Neurol 2016; 15 (05) 455-532
• 119 Khalil YA, Rabès JP, Boileau C, Varret M. APOE gene variants in primary dyslipidemia. Atherosclerosis 2021; 328: 11-22
• 120 Liu C-C, Liu C-C, Kanekiyo T, Xu H, Bu G. Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy. Nat Rev Neurol 2013; 9 (02) 106-118
• 121 Mahley RW, Rall Jr SC. Apolipoprotein E: far more than a lipid transport protein. Annu Rev Genomics Hum Genet 2000; 1: 507-537
• 122 Lahoz C, Schaefer EJ, Cupples LA. et al. Apolipoprotein E genotype and cardiovascular disease in the Framingham Heart Study. Atherosclerosis 2001; 154 (03) 529-537
• 123 Yassine HN, Finch CE. APOE alleles and diet in brain aging and Alzheimer's disease. Front Aging Neurosci 2020; 12: 150
• 124 Carvalho-Wells AL, Jackson KG, Lockyer S, Lovegrove JA, Minihane AM. APOE genotype influences triglyceride and C-reactive protein responses to altered dietary fat intake in UK adults. Am J Clin Nutr 2012; 96 (06) 1447-1453
• 125 Duong MT, Nasrallah IM, Wolk DA, Chang CCY, Chang T-Y. Cholesterol, atherosclerosis, and APOE in vascular contributions to cognitive impairment and dementia (VCID): potential mechanisms and therapy. Front Aging Neurosci 2021; 13: 647990
• 126 Bennet AM, Di Angelantonio E, Ye Z. et al. Association of apolipoprotein E genotypes with lipid levels and coronary risk. JAMA 2007; 298 (11) 1300-1311
• 127 Granér M, Kahri J, Varpula M. et al. Apolipoprotein E polymorphism is associated with both carotid and coronary atherosclerosis in patients with coronary artery disease. Nutr Metab Cardiovasc Dis 2008; 18 (04) 271-277
• 128 Berkowitz CL, Mosconi L, Rahman A, Scheyer O, Hristov H, Isaacson RS. Clinical application of APOE in Alzheimer's prevention: a precision medicine approach. J Prev Alzheimers Dis 2018; 5 (04) 245-252
• 129 Saif N, Sadek G, Bellara S, Hristov H, Isaacson RS. Brain health & dementia risk reduction. Pract Neurol 2019; 89-104
• 130 Geifman N, Brinton RD, Kennedy RE, Schneider LS, Butte AJ. Evidence for benefit of statins to modify cognitive decline and risk in Alzheimer's disease. Alzheimers Res Ther 2017; 9 (01) 10
• 131 Zhao N, Liu CC, Van Ingelgom AJ. et al. Apolipoprotein E4 impairs neuronal insulin signaling by trapping insulin receptor in the endosomes. Neuron 2017; 96 (01) 115-129.e5
• 132 Kivipelto M, Rovio S, Ngandu T. et al. Apolipoprotein E epsilon4 magnifies lifestyle risks for dementia: a population-based study. J Cell Mol Med 2008; 12 (6B): 2762-2771
• 133 Norwitz NG, Saif N, Ariza IE, Isaacson RS. Precision nutrition for Alzheimer's prevention in ApoE4 carriers. Nutrients 2021; 13 (04) 1362
• 134 Arellanes IC, Choe N, Solomon V. et al. Brain delivery of supplemental docosahexaenoic acid (DHA): a randomized placebo-controlled clinical trial. EBioMedicine 2020; 59: 102883
• 135 Yassine HN, Cordova I, He X. et al. Refining omega-3 supplementation trials in APOE4 carriers for dementia prevention. Alzheimers Dement 2020; 16: e039029
• 136 Nardiello P, Pantano D, Lapucci A, Stefani M, Casamenti F. Diet supplementation with hydroxytyrosol ameliorates brain pathology and restores cognitive functions in a mouse model of amyloid-β deposition. J Alzheimers Dis 2018; 63 (03) 1161-1172
• 137 Abuznait AH, Qosa H, Busnena BA, El Sayed KA, Kaddoumi A. Olive-oil-derived oleocanthal enhances β-amyloid clearance as a potential neuroprotective mechanism against Alzheimer's disease: in vitro and in vivo studies. ACS Chem Neurosci 2013; 4 (06) 973-982
• 138 Monti MC, Margarucci L, Tosco A, Riccio R, Casapullo A. New insights on the interaction mechanism between tau protein and oleocanthal, an extra-virgin olive-oil bioactive component. Food Funct 2011; 2 (07) 423-428
• 139 Daccache A, Lion C, Sibille N. et al. Oleuropein and derivatives from olives as tau aggregation inhibitors. Neurochem Int 2011; 58 (06) 700-707
• 140 Norton S, Matthews FE, Barnes DE, Yaffe K, Brayne C. Potential for primary prevention of Alzheimer's disease: an analysis of population-based data. Lancet Neurol 2014; 13 (08) 788-794
• 141 Maddock J, Cavadino A, Power C, Hyppönen E. 25-Hydroxyvitamin D, APOE ɛ4 genotype and cognitive function: findings from the 1958 British birth cohort. Eur J Clin Nutr 2015; 69 (04) 505-508
• 142 Aridi YS, Walker JL, Wright ORL. The Association between the Mediterranean dietary pattern and cognitive health: a systematic review. Nutrients 2017; 9 (07) 674
• 143 Samadi M, Moradi S, Moradinazar M, Mostafai R, Pasdar Y. Dietary pattern in relation to the risk of Alzheimer's disease: a systematic review. Neurol Sci 2019; 40 (10) 2031-2043
• 144 Bartochowski Z, Conway J, Wallach Y, Chakkamparambil B, Alakkassery S, Grossberg GT. Dietary interventions to prevent or delay Alzheimer's disease: what the evidence shows. Curr Nutr Rep 2020; 9 (03) 210-225
• 145 Cherian L, Wang Y, Fakuda K, Leurgans S, Aggarwal N, Morris M. Mediterranean-Dash Intervention for Neurodegenerative Delay (MIND) diet slows cognitive decline after stroke. J Prev Alzheimers Dis 2019; 6 (04) 267-273
• 146 Taylor MK, Sullivan DK, Swerdlow RH. et al. A high-glycemic diet is associated with cerebral amyloid burden in cognitively normal older adults. Am J Clin Nutr 2017; 106 (06) 1463-1470
• 147 Morris MC, Tangney CC. Dietary fat composition and dementia risk. Neurobiol Aging 2014; 35 (Suppl. 02) S59-S64
• 148 Zielińska MA, Białecka A, Pietruszka B, Hamułka J. Vegetables and fruit, as a source of bioactive substances, and impact on memory and cognitive function of elderly. Postepy Hig Med Dosw 2017; 71 (00) 267-280
• 149 Shinto L. Eating seafood and cognitive decline in older adults. Neurology 2016; 86 (22) e231-e233
• 150 Berti V, Walters M, Sterling J. et al. Mediterranean diet and 3-year Alzheimer brain biomarker changes in middle-aged adults. Neurology 2018; 90 (20) e1789-e1798
• 151 Scarmeas N, Stern Y, Mayeux R, Manly JJ, Schupf N, Luchsinger JA. Mediterranean diet and mild cognitive impairment. Arch Neurol 2009; 66 (02) 216-225
• 152 Wu L, Sun D. Adherence to Mediterranean diet and risk of developing cognitive disorders: An updated systematic review and meta-analysis of prospective cohort studies. Sci Rep 2017; 7: 41317-41317
• 153 Xie G, Zhou Q, Qiu CZ. et al. Ketogenic diet poses a significant effect on imbalanced gut microbiota in infants with refractory epilepsy. World J Gastroenterol 2017; 23 (33) 6164-6171
• 154 Ota M, Matsuo J, Ishida I. et al. Effect of a ketogenic meal on cognitive function in elderly adults: potential for cognitive enhancement. Psychopharmacology (Berl) 2016; 233 (21-22): 3797-3802
• 155 Alirezaei M, Kemball CC, Flynn CT, Wood MR, Whitton JL, Kiosses WB. Short-term fasting induces profound neuronal autophagy. Autophagy 2010; 6 (06) 702-710
• 156 Jamshed H, Beyl RA, Della Manna DL, Yang ES, Ravussin E, Peterson CM. Early time-restricted feeding improves 24-hour glucose levels and affects markers of the circadian clock, aging, and autophagy in humans. Nutrients 2019; 11 (06) 1234
• 157 Hu Y, Yang Y, Zhang M, Deng M, Zhang JJ. Intermittent fasting pretreatment prevents cognitive impairment in a rat model of chronic cerebral hypoperfusion. J Nutr 2017; 147 (07) 1437-1445
• 158 Hu Y, Zhang M, Chen Y, Yang Y, Zhang JJ. Postoperative intermittent fasting prevents hippocampal oxidative stress and memory deficits in a rat model of chronic cerebral hypoperfusion. Eur J Nutr 2019; 58 (01) 423-432
• 159 Schafer MJ, Dolgalev I, Alldred MJ, Heguy A, Ginsberg SD. Calorie restriction suppresses age-dependent hippocampal transcriptional signatures. PLoS One 2015; 10 (07) e0133923
• 160 Corley BT, Carroll RW, Hall RM, Weatherall M, Parry-Strong A, Krebs JD. Intermittent fasting in Type 2 diabetes mellitus and the risk of hypoglycaemia: a randomized controlled trial. Diabet Med 2018; 35 (05) 588-594
• 161 Qin B, Xun P, Jacobs Jr DR. et al. Intake of niacin, folate, vitamin B-6, and vitamin B-12 through young adulthood and cognitive function in midlife: the Coronary Artery Risk Development in Young Adults (CARDIA) study. Am J Clin Nutr 2017; 106 (04) 1032-1040
• 162 Román GC. MTHFR gene mutations: a potential marker of late-onset Alzheimer's disease?. J Alzheimers Dis 2015; 47 (02) 323-327
• 163 Schelke MW, Hackett K, Chen JL. et al. Nutritional interventions for Alzheimer's prevention: a clinical precision medicine approach. Ann N Y Acad Sci 2016; 1367 (01) 50-56
• 164 Velazquez R, Ferreira E, Knowles S. et al. Lifelong choline supplementation ameliorates Alzheimer's disease pathology and associated cognitive deficits by attenuating microglia activation. Aging Cell 2019; 18 (06) e13037
• 165 Ballaz SJ, Rebec GV. Neurobiology of vitamin C: expanding the focus from antioxidant to endogenous neuromodulator. Pharmacol Res 2019; 146: 104321
• 166 Masaki KH, Losonczy KG, Izmirlian G. et al. Association of vitamin E and C supplement use with cognitive function and dementia in elderly men. Neurology 2000; 54 (06) 1265-1272
• 167 Banerjee A, Khemka VK, Ganguly A, Roy D, Ganguly U, Chakrabarti S. Vitamin D and Alzheimer's disease: neurocognition to therapeutics. Int J Alzheimers Dis 2015; 2015: 192747
• 168 Wu A, Ying Z, Gomez-Pinilla F. Docosahexaenoic acid dietary supplementation enhances the effects of exercise on synaptic plasticity and cognition. Neuroscience 2008; 155 (03) 751-759
• 169 Barry AR, Dixon DL. Omega-3 fatty acids for the prevention of atherosclerotic cardiovascular disease. Pharmacotherapy 2021; 41 (12) 1056-1065
• 170 Doshi R, Majmundar M, Kumar A, Patel K, Vallabhajosyula S, Kalra A. Association of new-onset atrial fibrillation in patients taking high-dose fish oil. Eur J Intern Med 2021; 94: 110-111
• 171 Mecocci P, Boccardi V, Cecchetti R. et al. A long journey into aging, brain aging, and Alzheimer's disease following the oxidative stress tracks. J Alzheimers Dis 2018; 62 (03) 1319-1335
• 172 Holland TM, Agarwal P, Wang Y. et al. Dietary flavonols and risk of Alzheimer dementia. Neurology 2020; 94 (16) e1749-e1756
• 173 Mastroiacovo D, Kwik-Uribe C, Grassi D. et al. Cocoa flavanol consumption improves cognitive function, blood pressure control, and metabolic profile in elderly subjects: the Cocoa, Cognition, and Aging (CoCoA) study – a randomized controlled trial. Am J Clin Nutr 2015; 101 (03) 538-548
• 174 Brickman AM, Khan UA, Provenzano FA. et al. Enhancing dentate gyrus function with dietary flavanols improves cognition in older adults. Nat Neurosci 2014; 17 (12) 1798-1803
• 175 Sansone R, Rodriguez-Mateos A, Heuel J. et al; Flaviola Consortium, European Union 7th Framework Program. Cocoa flavanol intake improves endothelial function and Framingham Risk Score in healthy men and women: a randomised, controlled, double-masked trial: the Flaviola Health Study. Br J Nutr 2015; 114 (08) 1246-1255
• 176 Davison K, Coates AM, Buckley JD, Howe PR. Effect of cocoa flavanols and exercise on cardiometabolic risk factors in overweight and obese subjects. Int J Obes 2008; 32 (08) 1289-1296
• 177 Sansone R, Ottaviani JI, Rodriguez-Mateos A. et al. Methylxanthines enhance the effects of cocoa flavanols on cardiovascular function: randomized, double-masked controlled studies. Am J Clin Nutr 2017; 105 (02) 352-360
• 178 Fisher ND, Hughes M, Gerhard-Herman M, Hollenberg NK. Flavanol-rich cocoa induces nitric-oxide-dependent vasodilation in healthy humans. J Hypertens 2003; 21 (12) 2281-2286
• 179 Heiss C, Kleinbongard P, Dejam A. et al. Acute consumption of flavanol-rich cocoa and the reversal of endothelial dysfunction in smokers. J Am Coll Cardiol 2005; 46 (07) 1276-1283
• 180 Fisher ND, Hollenberg NK. Aging and vascular responses to flavanol-rich cocoa. J Hypertens 2006; 24 (08) 1575-1580
• 181 Desideri G, Kwik-Uribe C, Grassi D. et al. Benefits in cognitive function, blood pressure, and insulin resistance through cocoa flavanol consumption in elderly subjects with mild cognitive impairment: the Cocoa, Cognition, and Aging (CoCoA) study. Hypertension 2012; 60 (03) 794-801
• 182 Voulgaropoulou SD, van Amelsvoort TAMJ, Prickaerts J, Vingerhoets C. The effect of curcumin on cognition in Alzheimer's disease and healthy aging: a systematic review of pre-clinical and clinical studies. Brain Res 2019; 1725: 146476
• 183 Ghosh S, Banerjee S, Sil PC. The beneficial role of curcumin on inflammation, diabetes and neurodegenerative disease: a recent update. Food Chem Toxicol 2015; 83: 111-124
• 184 Brondino N, Re S, Boldrini A. et al. Curcumin as a therapeutic agent in dementia: a mini systematic review of human studies. ScientificWorldJournal 2014; 2014: 174282
• 185 Mishra S, Palanivelu K. The effect of curcumin (turmeric) on Alzheimer's disease: an overview. Ann Indian Acad Neurol 2008; 11 (01) 13-19
• 186 Anstey KJ, Mack HA, Cherbuin N. Alcohol consumption as a risk factor for dementia and cognitive decline: meta-analysis of prospective studies. Am J Geriatr Psychiatry 2009; 17 (07) 542-555
• 187 Mukamal KJ, Kuller LH, Fitzpatrick AL, Longstreth Jr WT, Mittleman MA, Siscovick DS. Prospective study of alcohol consumption and risk of dementia in older adults. JAMA 2003; 289 (11) 1405-1413
• 188 Luchsinger JA, Tang MX, Siddiqui M, Shea S, Mayeux R. Alcohol intake and risk of dementia. J Am Geriatr Soc 2004; 52 (04) 540-546
• 189 Schwarzinger M, Pollock BG, Hasan OSM, Dufouil C, Rehm J. QalyDays Study Group. Contribution of alcohol use disorders to the burden of dementia in France 2008-13: a nationwide retrospective cohort study. Lancet Public Health 2018; 3 (03) e124-e132
• 190 Anttila T, Helkala EL, Viitanen M. et al. Alcohol drinking in middle age and subsequent risk of mild cognitive impairment and dementia in old age: a prospective population based study. BMJ 2004; 329 (7465): 539
• 191 Sabia S, Fayosse A, Dumurgier J. et al. Alcohol consumption and risk of dementia: 23 year follow-up of Whitehall II cohort study. BMJ 2018; 362: k2927
• 192 Brini S, Sohrabi HR, Peiffer JJ. et al. Physical activity in preventing Alzheimer's disease and cognitive decline: a narrative review. Sports Med 2018; 48 (01) 29-44
• 193 Ito S. High-intensity interval training for health benefits and care of cardiac diseases - The key to an efficient exercise protocol. World J Cardiol 2019; 11 (07) 171-188
• 194 Weston M, Taylor KL, Batterham AM, Hopkins WG. Effects of low-volume high-intensity interval training (HIT) on fitness in adults: a meta-analysis of controlled and non-controlled trials. Sports Med 2014; 44 (07) 1005-1017
• 195 Tokgöz S, Claassen JAHR. Exercise as potential therapeutic target to modulate Alzheimer's disease pathology in APOE ε4 carriers: a systematic review. Cardiol Ther 2021; 10 (01) 67-88
• 196 Racil G, Ben Ounis O, Hammouda O. et al. Effects of high vs. moderate exercise intensity during interval training on lipids and adiponectin levels in obese young females. Eur J Appl Physiol 2013; 113 (10) 2531-2540
• 197 Søgaard D, Lund MT, Scheuer CM. et al. High-intensity interval training improves insulin sensitivity in older individuals. Acta Physiol (Oxf) 2018; 222 (04) e13009
• 198 Elliott AD, Rajopadhyaya K, Bentley DJ, Beltrame JF, Aromataris EC. Interval training versus continuous exercise in patients with coronary artery disease: a meta-analysis. Heart Lung Circ 2015; 24 (02) 149-157
• 199 Garber CE, Blissmer B, Deschenes MR. et al; American College of Sports Medicine. American College of Sports Medicine position stand. Quantity and quality of exercise for developing and maintaining cardiorespiratory, musculoskeletal, and neuromotor fitness in apparently healthy adults: guidance for prescribing exercise. Med Sci Sports Exerc 2011; 43 (07) 1334-1359
• 200 Kodama S, Saito K, Tanaka S. et al. Cardiorespiratory fitness as a quantitative predictor of all-cause mortality and cardiovascular events in healthy men and women: a meta-analysis. JAMA 2009; 301 (19) 2024-2035
• 201 Foster C, Farland CV, Guidotti F. et al. The effects of high intensity interval training vs steady state training on aerobic and anaerobic capacity. J Sports Sci Med 2015; 14 (04) 747-755
• 202 Liou K, Ho S, Fildes J, Ooi SY. High intensity interval versus moderate intensity continuous training in patients with coronary artery disease: a meta-analysis of physiological and clinical parameters. Heart Lung Circ 2016; 25 (02) 166-174
• 203 Luks HJ. Zone 2 Heart Rate Training For Longevity and Performance. 2022 Accessed November 14, 2022 at: https://www.howardluksmd.com/zone-2-hr-training-live-longer-less-injury/
• 204 Liu-Ambrose T, Barha CK, Best JR. Physical activity for brain health in older adults. Appl Physiol Nutr Metab 2018; 43 (11) 1105-1112
• 205 Suo C, Singh MF, Gates N. et al. Therapeutically relevant structural and functional mechanisms triggered by physical and cognitive exercise. Mol Psychiatry 2016; 21 (11) 1633-1642
• 206 Barha CK, Davis JC, Falck RS, Nagamatsu LS, Liu-Ambrose T. Sex differences in exercise efficacy to improve cognition: a systematic review and meta-analysis of randomized controlled trials in older humans. Front Neuroendocrinol 2017; 46: 71-85
• 207 Baumgart M, Snyder HM, Carrillo MC, Fazio S, Kim H, Johns H. Summary of the evidence on modifiable risk factors for cognitive decline and dementia: a population-based perspective. Alzheimers Dement 2015; 11 (06) 718-726
• 208 Barnes DE, Yaffe K. The projected effect of risk factor reduction on Alzheimer's disease prevalence. Lancet Neurol 2011; 10 (09) 819-828
• 209 Lennon MJ, Makkar SR, Crawford JD, Sachdev PS. Midlife hypertension and Alzheimer's disease: a systematic review and meta-analysis. J Alzheimers Dis 2019; 71 (01) 307-316
• 210 Hughes TM, Sink KM. Hypertension and its role in cognitive function: current evidence and challenges for the future. Am J Hypertens 2016; 29 (02) 149-157
• 211 Peters R, Warwick J, Anstey KJ, Anderson CS. Blood pressure and dementia: what the SPRINT-MIND trial adds and what we still need to know. Neurology 2019; 92 (21) 1017-1018
• 212 Williamson JD, Pajewski NM, Auchus AP. et al; SPRINT MIND Investigators for the SPRINT Research Group. Effect of intensive vs standard blood pressure control on probable dementia: a randomized clinical trial. JAMA 2019; 321 (06) 553-561
• 213 Nasrallah IM, Gaussoin SA, Pomponio R. et al; SPRINT Research Group. Association of intensive vs standard blood pressure control with magnetic resonance imaging biomarkers of Alzheimer disease: secondary analysis of the SPRINT MIND Randomized Trial. JAMA Neurol 2021; 78 (05) 568-577
• 214 Hajjar I, Okafor M, McDaniel D. et al. Effects of candesartan vs lisinopril on neurocognitive function in older adults with executive mild cognitive impairment: a randomized clinical trial. JAMA Netw Open 2020; 3 (08) e2012252-e2012252
• 215 Liu C-H, Sung P-S, Li Y-R. et al. Telmisartan use and risk of dementia in type 2 diabetes patients with hypertension: a population-based cohort study. PLoS Med 2021; 18 (07) e1003707
• 216 Holm H, Ricci F, Di Martino G. et al. Beta-blocker therapy and risk of vascular dementia: a population-based prospective study. Vascul Pharmacol 2020; 125-126: 106649
• 217 Wingo TS, Cutler DJ, Wingo AP. et al. Association of early-onset Alzheimer disease with elevated low-density lipoprotein cholesterol levels and rare genetic coding variants of APOB. JAMA Neurol 2019; 76 (07) 809-817
• 218 Iwagami M, Qizilbash N, Gregson J. et al. Blood cholesterol and risk of dementia in more than 1·8 million people over two decades: a retrospective cohort study. Lancet Healthy Longev 2021; 2 (08) e498-e506
• 219 Feringa FM, van der Kant R. Cholesterol and Alzheimer's disease; from risk genes to pathological effects. Front Aging Neurosci 2021; 13: 690372
• 220 Anstey KJ, Ashby-Mitchell K, Peters R. Updating the evidence on the association between serum cholesterol and risk of late-life dementia: review and meta-analysis. J Alzheimers Dis 2017; 56 (01) 215-228
• 221 Loera-Valencia R, Goikolea J, Parrado-Fernandez C, Merino-Serrais P, Maioli S. Alterations in cholesterol metabolism as a risk factor for developing Alzheimer's disease: potential novel targets for treatment. J Steroid Biochem Mol Biol 2019; 190: 104-114
• 222 Vance JE. Dysregulation of cholesterol balance in the brain: contribution to neurodegenerative diseases. Dis Model Mech 2012; 5 (06) 746-755
• 223 Proitsi P, Kim M, Whiley L. et al. Association of blood lipids with Alzheimer's disease: a comprehensive lipidomics analysis. Alzheimers Dement 2017; 13 (02) 140-151
• 224 Li R, Wang T-J, Lyu P-Y. et al. Effects of plasma lipids and statins on cognitive function. Chin Med J (Engl) 2018; 131 (04) 471-476
• 225 Li X, Song D, Leng SX. Link between type 2 diabetes and Alzheimer's disease: from epidemiology to mechanism and treatment. Clin Interv Aging 2015; 10: 549-560
• 226 Tabassum S, Misrani A, Yang L. Exploiting common aspects of obesity and Alzheimer's disease. Front Hum Neurosci 2020; 14: 602360
• 227 Terzo S, Amato A, Mulè F. From obesity to Alzheimer's disease through insulin resistance. J Diabetes Complications 2021; 35 (11) 108026
• 228 Bendlin BB. Antidiabetic therapies and Alzheimer disease. Dialogues Clin Neurosci 2019; 21 (01) 83-91
• 229 Angevaare MJ, Vonk JMJ, Bertola L. et al. Predictors of incident mild cognitive impairment and its course in a diverse community-based population. Neurology 2022; 98 (01) e15-e26
• 230 Sharp ES, Gatz M. Relationship between education and dementia: an updated systematic review. Alzheimer Dis Assoc Disord 2011; 25 (04) 289-304
• 231 Wada M, Noda Y, Shinagawa S. et al; Alzheimer's Disease Neuroimaging Initiative. Effect of education on Alzheimer's disease-related neuroimaging biomarkers in healthy controls, and participants with mild cognitive impairment and Alzheimer's disease: a cross-sectional study. J Alzheimers Dis 2018; 63 (02) 861-869
• 232 Leggieri M, Thaut MH, Fornazzari L. et al. Music intervention approaches for Alzheimer's disease: a review of the literature. Front Neurosci 2019; 13: 132
• 233 Bae S, Lee S, Harada K. et al. Engagement in lifestyle activities is associated with increased Alzheimer's disease-associated cortical thickness and cognitive performance in older adults. J Clin Med 2020; 9 (05) 1424
• 234 Landau SM, Marks SM, Mormino EC. et al. Association of lifetime cognitive engagement and low β-amyloid deposition. Arch Neurol 2012; 69 (05) 623-629
• 235 Friedler B, Crapser J, McCullough L. One is the deadliest number: the detrimental effects of social isolation on cerebrovascular diseases and cognition. Acta Neuropathol 2015; 129 (04) 493-509
• 236 Huang H, Wang L, Cao M. et al. Isolation housing exacerbates Alzheimer's disease-like pathophysiology in aged APP/PS1 mice. Int J Neuropsychopharmacol 2015; 18 (07) pyu116
• 237 Hsiao YH, Chen PS, Chen SH, Gean PW. The involvement of Cdk5 activator p35 in social isolation-triggered onset of early Alzheimer's disease-related cognitive deficit in the transgenic mice. Neuropsychopharmacology 2011; 36 (09) 1848-1858
• 238 Powell ND, Sloan EK, Bailey MT. et al. Social stress up-regulates inflammatory gene expression in the leukocyte transcriptome via β-adrenergic induction of myelopoiesis. Proc Natl Acad Sci U S A 2013; 110 (41) 16574-16579
• 239 Miranda M, Morici JF, Zanoni MB, Bekinschtein P. Brain-derived neurotrophic factor: a key molecule for memory in the healthy and the pathological brain. Front Cell Neurosci 2019; 13: 363-363
• 240 Anstey KJ, Peters R, Mortby ME. et al. Association of sex differences in dementia risk factors with sex differences in memory decline in a population-based cohort spanning 20-76 years. Sci Rep 2021; 11 (01) 7710
• 241 Murata C, Saito T, Saito M, Kondo K. The association between social support and incident dementia: a 10-year follow-up study in Japan. Int J Environ Res Public Health 2019; 16 (02) 239
• 242 Ruthirakuhan M, Luedke AC, Tam A, Goel A, Kurji A, Garcia A. Use of physical and intellectual activities and socialization in the management of cognitive decline of aging and in dementia: a review. J Aging Res 2012; 2012: 384875-384875
• 243 Cotterell N, Buffel T, Phillipson C. Preventing social isolation in older people. Maturitas 2018; 113: 80-84
• 244 Kaufman Y. Stress, Memory, and Meaning. B'Or Ha'Torah 2012;22;
• 245 Ouanes S, Popp J. High cortisol and the risk of dementia and Alzheimer's disease: a review of the literature. Front Aging Neurosci 2019; 11: 43-43
• 246 Donovan NJ, Hsu DC, Dagley AS. et al. Depressive symptoms and biomarkers of Alzheimer's disease in cognitively normal older adults. J Alzheimers Dis 2015; 46 (01) 63-73
• 247 Peavy GM, Jacobson MW, Salmon DP. et al. The influence of chronic stress on dementia-related diagnostic change in older adults. Alzheimer Dis Assoc Disord 2012; 26 (03) 260-266
• 248 Becker E, Orellana Rios CL, Lahmann C, Rücker G, Bauer J, Boeker M. Anxiety as a risk factor of Alzheimer's disease and vascular dementia. Br J Psychiatry 2018; 213 (05) 654-660
• 249 Johansson L, Guo X, Waern M. et al. Midlife psychological stress and risk of dementia: a 35-year longitudinal population study. Brain 2010; 133 (Pt 8): 2217-2224
• 250 Yaffe K, Vittinghoff E, Lindquist K. et al. Posttraumatic stress disorder and risk of dementia among US veterans. Arch Gen Psychiatry 2010; 67 (06) 608-613
• 251 Rafferty LA, Cawkill PE, Stevelink SAM, Greenberg K, Greenberg N. Dementia, post-traumatic stress disorder and major depressive disorder: a review of the mental health risk factors for dementia in the military veteran population. Psychol Med 2018; 48 (09) 1400-1409
• 252 Fuhrer R, Dufouil C, Dartigues JF. PAQUID Study. Exploring sex differences in the relationship between depressive symptoms and dementia incidence: prospective results from the PAQUID Study. J Am Geriatr Soc 2003; 51 (08) 1055-1063
• 253 Dal Forno G, Palermo MT, Donohue JE, Karagiozis H, Zonderman AB, Kawas CH. Depressive symptoms, sex, and risk for Alzheimer's disease. Ann Neurol 2005; 57 (03) 381-387
• 254 Burke SL, Cadet T, Alcide A, O'Driscoll J, Maramaldi P. Psychosocial risk factors and Alzheimer's disease: the associative effect of depression, sleep disturbance, and anxiety. Aging Ment Health 2018; 22 (12) 1577-1584
• 255 Dafsari FS, Jessen F. Depression - an underrecognized target for prevention of dementia in Alzheimer's disease. Transl Psychiatry 2020; 10 (01) 160
• 256 Cirrito JR, Wallace CE, Yan P. et al. Effect of escitalopram on Aβ levels and plaque load in an Alzheimer mouse model. Neurology 2020; 95 (19) e2666-e2674
• 257 Hüttenrauch M, Lopez-Noguerola JS, Castro-Obregón S. Connecting mind-body therapy-mediated effects to pathological features of Alzheimer's disease. J Alzheimers Dis 2021; 82 (s1): S65-S90
• 258 Sumathi R, Umapriya M, Ganesh AS. Meditation Helps to Overcome Alzheimer's? A Review Based on Psychiatric Reasons. Zeichen Journal 2021;7(03)
• 259 Damian AE. Reserve and Mindfulness Meditation: Preventative Therapies for Alzheimer's Disease—An Integrative Review [Psy.D.]. Ann Arbor, CA: Institute of Integral Studies; 2018
• 260 eun Lee G, ho Kim S, chul Jung I, won Kang H. Meditation for Alzheimer's disease: systematic review and meta-analysis. J of Oriental Neuropsychiatry 2019; 30 (03) 237-249
• 261 Fan L, Xu W, Cai Y, Hu Y, Wu C. Sleep duration and the risk of dementia: a systematic review and meta-analysis of prospective cohort studies. J Am Med Dir Assoc 2019; 20 (12) 1480-1487.e5
• 262 Yaffe K, Falvey CM, Hoang T. Connections between sleep and cognition in older adults. Lancet Neurol 2014; 13 (10) 1017-1028
• 263 Westwood AJ, Beiser A, Jain N. et al. Prolonged sleep duration as a marker of early neurodegeneration predicting incident dementia. Neurology 2017; 88 (12) 1172-1179
• 264 Lu Y, Sugawara Y, Zhang S, Tomata Y, Tsuji I. Changes in sleep duration and the risk of incident dementia in the elderly Japanese: the Ohsaki Cohort 2006 Study. Sleep 2018; 41 (10) 41
• 265 Hahn EA, Wang HX, Andel R, Fratiglioni L. A change in sleep pattern may predict Alzheimer disease. Am J Geriatr Psychiatry 2014; 22 (11) 1262-1271
• 266 Lucey BP. It's complicated: the relationship between sleep and Alzheimer's disease in humans. Neurobiol Dis 2020; 144: 105031
• 267 Irwin MR, Vitiello MV. Implications of sleep disturbance and inflammation for Alzheimer's disease dementia. Lancet Neurol 2019; 18 (03) 296-306
• 268 Wang C, Holtzman DM. Bidirectional relationship between sleep and Alzheimer's disease: role of amyloid, tau, and other factors. Neuropsychopharmacology 2020; 45 (01) 104-120
• 269 Minakawa EN, Wada K, Nagai Y. Sleep disturbance as a potential modifiable risk factor for Alzheimer's disease. Int J Mol Sci 2019; 20 (04) 803
• 270 Mander BA. Local sleep and Alzheimer's disease pathophysiology. Front Neurosci 2020; 14: 525970-525970
• 271 Robbins R, Quan SF, Weaver MD, Bormes G, Barger LK, Czeisler CA. Examining sleep deficiency and disturbance and their risk for incident dementia and all-cause mortality in older adults across 5 years in the United States. Aging (Albany NY) 2021; 13 (03) 3254-3268
• 272 Sabia S, Fayosse A, Dumurgier J. et al. Association of sleep duration in middle and old age with incidence of dementia. Nat Commun 2021; 12 (01) 2289
• 273 Nedergaard M, Goldman SA. Glymphatic failure as a final common pathway to dementia. Science 2020; 370 (6512): 50-56
• 274 Shokri-Kojori E, Wang GJ, Wiers CE. et al. β-Amyloid accumulation in the human brain after one night of sleep deprivation. Proc Natl Acad Sci U S A 2018; 115 (17) 4483-4488
• 275 Ooms S, Overeem S, Besse K, Rikkert MO, Verbeek M, Claassen JA. Effect of 1 night of total sleep deprivation on cerebrospinal fluid β-amyloid 42 in healthy middle-aged men: a randomized clinical trial. JAMA Neurol 2014; 71 (08) 971-977
• 276 Pase MP, Himali JJ, Grima NA. et al. Sleep architecture and the risk of incident dementia in the community. Neurology 2017; 89 (12) 1244-1250
• 277 Erickson KI, Banducci SE, Weinstein AM. et al. The brain-derived neurotrophic factor Val66Met polymorphism moderates an effect of physical activity on working memory performance. Psychol Sci 2013; 24 (09) 1770-1779
• 278 Tseng L-Y, Huang S-T, Peng L-N, Chen L-K, Hsiao F-Y. Benzodiazepines, z-hypnotics, and risk of dementia: special considerations of half-lives and concomitant use. Neurotherapeutics 2020; 17 (01) 156-164
• 279 Gray SL, Anderson ML, Dublin S. et al. Cumulative use of strong anticholinergics and incident dementia: a prospective cohort study. JAMA Intern Med 2015; 175 (03) 401-407
• 280 Liguori C, Maestri M, Spanetta M. et al. Sleep-disordered breathing and the risk of Alzheimer's disease. Sleep Med Rev 2021; 55: 101375
• 281 Chang W-P, Liu M-E, Chang W-C. et al. Sleep apnea and the risk of dementia: a population-based 5-year follow-up study in Taiwan. PLoS One 2013; 8 (10) e78655-e78655
• 282 Zacharias HU, Weihs A, Habes M. et al. Association between obstructive sleep apnea and brain white matter hyperintensities in a population-based cohort in Germany. JAMA Netw Open 2021; 4 (10) e2128225-e2128225
• 283 Mitchell BL, Thorp JG, Evans DM, Nyholt DR, Martin NG, Lupton MK. Exploring the genetic relationship between hearing impairment and Alzheimer's disease. Alzheimers Dement (Amst) 2020; 12 (01) e12108
• 284 Zheng Y, Fan S, Liao W, Fang W, Xiao S, Liu J. Hearing impairment and risk of Alzheimer's disease: a meta-analysis of prospective cohort studies. Neurol Sci 2017; 38 (02) 233-239
• 285 Bagheri F, Borhaninejad V, Rashedi V. Alzheimer's disease and hearing loss among older adults: a literature review. Int J Psychol Behav Sci 2018; 8 (05) 77-80
• 286 Sivanandam TM, Thakur MK. Traumatic brain injury: a risk factor for Alzheimer's disease. Neurosci Biobehav Rev 2012; 36 (05) 1376-1381
• 287 Panicio CFT, Maluta H, Salata FL, Brambilla RR, Dominato AAG. Smoking as a triggering factor for Alzheimer's disease: an integrative review. Res, Soc Dev 2020; 9: e4389119971
• 288 Niu H, Qu Y, Li Z. et al. Smoking and risk for Alzheimer disease: a meta-analysis based on both case-control and cohort study. J Nerv Ment Dis 2018; 206 (09) 680-685
• 289 Kamer AR, Craig RG, Niederman R, Fortea J, de Leon MJ. Periodontal disease as a possible cause for Alzheimer's disease. Periodontol 2000 2020; 83 (01) 242-271
• 290 Chen C-K, Wu Y-T, Chang Y-C. Association between chronic periodontitis and the risk of Alzheimer's disease: a retrospective, population-based, matched-cohort study. Alzheimers Res Ther 2017; 9 (01) 56
• 291 Beydoun MA, Beydoun HA, Hossain S, El-Hajj ZW, Weiss J, Zonderman AB. Clinical and bacterial markers of periodontitis and their association with incident all-cause and Alzheimer's disease dementia in a large national survey. J Alzheimers Dis 2020; 75 (01) 157-172
• 292 Kamer AR, Pushalkar S, Gulivindala D. et al. Periodontal dysbiosis associates with reduced CSF Aβ42 in cognitively normal elderly. Alzheimers Dement (Amst) 2021; 13 (01) e12172
• 293 Periodontal Disease [online]. Accessed November 14, 2022 at: https://www.cdc.gov/oralhealth/conditions/periodontal-disease.html
• 294 Abbayya K, Puthanakar NY, Naduwinmani S, Chidambar YS. Association between periodontitis and Alzheimer's disease. N Am J Med Sci 2015; 7 (06) 241-246
• 295 Sadrameli M, Bathini P, Alberi L. Linking mechanisms of periodontitis to Alzheimer's disease. Curr Opin Neurol 2020; 33 (02) 230-238
• 296 Liccardo D, Marzano F, Carraturo F. et al. Potential bidirectional relationship between periodontitis and Alzheimer's disease. Front Physiol 2020; 11: 683
• 297 Choi S, Kim K, Chang J. et al. Association of chronic periodontitis on Alzheimer's disease or vascular dementia. J Am Geriatr Soc 2019; 67 (06) 1234-1239
• 298 Rice AO. Alzheimer's disease and oral-systemic health: bidirectional care integration improving outcomes. Front Oral Health 2021; 2: 674329
• 299 Kraus N. Biological impact of music and software-based auditory training. J Commun Disord 2012; 45 (06) 403-410
• 300 What is precision medicine? [online]. Accessed November 14, 2022 at: https://medlineplus.gov/genetics/understanding/precisionmedicine/definition/
• 301 Ashley EA, Butte AJ, Wheeler MT. et al. Clinical assessment incorporating a personal genome. Lancet 2010; 375 (9725): 1525-1535
• 302 Berg JS, Amendola LM, Eng C. et al; Members of the CSER Actionability and Return of Results Working Group. Processes and preliminary outputs for identification of actionable genes as incidental findings in genomic sequence data in the Clinical Sequencing Exploratory Research Consortium. Genet Med 2013; 15 (11) 860-867
• 303 Burns DK, Chiang C, Welsh-Bohmer KA. et al. The TOMMORROW study: design of an Alzheimer's disease delay-of-onset clinical trial. Alzheimers Dement (N Y) 2019; 5: 661-670
• 304 Cacabelos R. Pharmacogenomics in Alzheimer's disease. Methods Mol Biol 2008; 448: 213-357
• 305 Krissaane I, De Niz C, Gutiérrez-Sacristán A. et al. Scalability and cost-effectiveness analysis of whole genome-wide association studies on Google Cloud Platform and Amazon Web Services. J Am Med Inform Assoc 2020; 27 (09) 1425-1430
• 306 Phil Huber JO. Limitations Persist in Growth of Precision Medicine. 2021 Accessed November 14, 2022 at: https://www.drugtopics.com/view/limitations-persist-in-growth-of-precision-medicine
• 307 Lleó A, Suárez-Calvet M. Race and Alzheimer disease biomarkers: a neglected race. Neurol Genet 2021; 7 (02) e574
• 308 Schindler SE, Cruchaga C, Joseph A. et al. African Americans have differences in CSF soluble TREM2 and associated genetic variants. Neurol Genet 2021; 7 (02) e571
• 309 Vega IE, Cabrera LY, Wygant CM, Velez-Ortiz D, Counts SE. Alzheimer's disease in the Latino community: intersection of genetics and social determinants of health. J Alzheimers Dis 2017; 58 (04) 979-992
• 310 Kalaria RN. The pathology and pathophysiology of vascular dementia. Neuropharmacology 2018; 134 (Pt B): 226-239
• 311 Panegyres PK, Chen H-Y. Differences between early and late onset Alzheimer's disease. Am J Neurodegener Dis 2013; 2 (04) 300-306
• 312 Stoker TB, Greenland JC. eds. Parkinson's Disease: Pathogenesis and Clinical Aspects. Brisbane (AU): Codon Publications Copyright © 2018 Codon Publications; 2018
• 313 Podcasy JL, Epperson CN. Considering sex and gender in Alzheimer disease and other dementias. Dialogues Clin Neurosci 2016; 18 (04) 437-446
• 314 Armstrong MJ, Litvan I, Lang AE. et al. Criteria for the diagnosis of corticobasal degeneration. Neurology 2013; 80 (05) 496-503
• 315 Ruitenberg A, Ott A, van Swieten JC, Hofman A, Breteler MM. Incidence of dementia: does gender make a difference?. Neurobiol Aging 2001; 22 (04) 575-580
• 316 Reekes TH, Higginson CI, Ledbetter CR, Sathivadivel N, Zweig RM, Disbrow EA. Sex specific cognitive differences in Parkinson disease. NPJ Parkinsons Dis 2020; 6: 7
• 317 Park HK, Ilango SD, Litvan I. Environmental risk factors for progressive supranuclear palsy. J Mov Disord 2021; 14 (02) 103-113
• 318 Constantinides VC, Paraskevas GP, Paraskevas PG, Stefanis L, Kapaki E. Corticobasal degeneration and corticobasal syndrome: a review. Clin Park Relat Disord 2019; 1: 66-71
• 319 Graff-Radford J, Yong KXX, Apostolova LG. et al. New insights into atypical Alzheimer's disease in the era of biomarkers. Lancet Neurol 2021; 20 (03) 222-234
• 320 Graham NL, Emery T, Hodges JR. Distinctive cognitive profiles in Alzheimer's disease and subcortical vascular dementia. J Neurol Neurosurg Psychiatry 2004; 75 (01) 61-71
• 321 Joubert S, Gour N, Guedj E. et al. Early-onset and late-onset Alzheimer's disease are associated with distinct patterns of memory impairment. Cortex 2016; 74: 217-232
• 322 Park HK, Choi SH, Park SA. et al. Cognitive profiles and neuropsychiatric symptoms in Korean early-onset Alzheimer's disease patients: a CREDOS study. J Alzheimers Dis 2015; 44 (02) 661-673
• 323 Koedam ELGE, Lauffer V, van der Vlies AE, van der Flier WM, Scheltens P, Pijnenburg YAL. Early-versus late-onset Alzheimer's disease: more than age alone. J Alzheimers Dis 2010; 19 (04) 1401-1408
• 324 Deleon J, Miller BL. Frontotemporal dementia. In: Geschwind DH, Paulson HL, Klein C. eds. Handbook of Clinical Neurology. Elsevier; 2018: 409-430
• 325 Vasilevskaya A, Taghdiri F, Multani N. et al. PET tau imaging and motor impairments differ between corticobasal syndrome and progressive supranuclear palsy with and without Alzheimer's disease biomarkers. Front Neurol 2020; 11: 574
• 326 Gao X, Simon KC, Han J, Schwarzschild MA, Ascherio A. Family history of melanoma and Parkinson disease risk. Neurology 2009; 73 (16) 1286-1291
• 327 Rogalski E, Johnson N, Weintraub S, Mesulam M. Increased frequency of learning disability in patients with primary progressive aphasia and their first-degree relatives. Arch Neurol 2008; 65 (02) 244-248
• 328 Culebras A, Anwar S. Sleep apnea is a risk factor for stroke and vascular dementia. Curr Neurol Neurosci Rep 2018; 18 (08) 53
• 329 Shi L, Chen S-J, Ma M-Y. et al. Sleep disturbances increase the risk of dementia: a systematic review and meta-analysis. Sleep Med Rev 2018; 40: 4-16
• 330 Falgàs N, Walsh CM, Neylan TC, Grinberg LT. Deepen into sleep and wake patterns across Alzheimer's disease phenotypes. Alzheimers Dement 2021; 17 (08) 1403-1406
• 331 Sani TP, Bond RL, Marshall CR. et al. Sleep symptoms in syndromes of frontotemporal dementia and Alzheimer's disease: a proof-of-principle behavioural study. eNeurologicalSci 2019; 17: 100212-100212
• 332 Walsh CM, Ruoff L, Walker K. et al. Sleepless night and day, the plight of progressive supranuclear palsy. Sleep 2017; 40 (11) 40
• 333 Smith EE. Clinical presentations and epidemiology of vascular dementia. Clin Sci (Lond) 2017; 131 (11) 1059-1068
• 334 Tanaka H, Hashimoto M, Fukuhara R. et al. Relationship between dementia severity and behavioural and psychological symptoms in early-onset Alzheimer's disease. Psychogeriatrics 2015; 15 (04) 242-247
• 335 Cheran G, Silverman H, Manoochehri M. et al. Psychiatric symptoms in preclinical behavioural-variant frontotemporal dementia in MAPT mutation carriers. J Neurol Neurosurg Psychiatry 2018; 89 (05) 449-455
• 336 Wittwer JE, Webster KE, Menz HB. A longitudinal study of measures of walking in people with Alzheimer's disease. Gait Posture 2010; 32 (01) 113-117
• 337 Dai MH, Zheng H, Zeng LD, Zhang Y. The genes associated with early-onset Alzheimer's disease. Oncotarget 2017; 9 (19) 15132-15143
• 338 Bandres-Ciga S, Diez-Fairen M, Kim JJ, Singleton AB. Genetics of Parkinson's disease: an introspection of its journey towards precision medicine. Neurobiol Dis 2020; 137: 104782
• 339 Greaves CV, Rohrer JD. An update on genetic frontotemporal dementia. J Neurol 2019; 266 (08) 2075-2086
• 340 Sha SJ, Boxer A. Treatment implications of C9ORF72. Alzheimers Res Ther 2012; 4 (06) 46-46
• 341 Richardson JR, Roy A, Shalat SL. et al. Elevated serum pesticide levels and risk for Alzheimer disease. JAMA Neurol 2014; 71 (03) 284-290
• 342 Perez-Lasierra JL, Casajús JA, Casasnovas JA. et al. Can physical activity reduce the risk of cognitive decline in apolipoprotein e4 carriers? A systematic review. Int J Environ Res Public Health 2021; 18 (14) 7238
• 343 Macaron T, Giudici KV, Bowman GL. et al. Associations of omega-3 fatty acids with brain morphology and volume in cognitively healthy older adults: a narrative review. Ageing Res Rev 2021; 67: 101300
• 344 Jernerén F, Elshorbagy AK, Oulhaj A, Smith SM, Refsum H, Smith AD. Brain atrophy in cognitively impaired elderly: the importance of long-chain ω-3 fatty acids and B vitamin status in a randomized controlled trial. Am J Clin Nutr 2015; 102 (01) 215-221
• 345 Annweiler C, Llewellyn DJ, Beauchet O. Low serum vitamin D concentrations in Alzheimer's disease: a systematic review and meta-analysis. J Alzheimers Dis 2013; 33 (03) 659-674
• 346 Annweiler C, Montero-Odasso M, Llewellyn DJ, Richard-Devantoy S, Duque G, Beauchet O. Meta-analysis of memory and executive dysfunctions in relation to vitamin D. J Alzheimers Dis 2013; 37 (01) 147-171
• 347 Smith AD, Smith SM, de Jager CA. et al. Homocysteine-lowering by B vitamins slows the rate of accelerated brain atrophy in mild cognitive impairment: a randomized controlled trial. PLoS One 2010; 5 (09) e12244
• 348 Price BR, Wilcock DM, Weekman EM. Hyperhomocysteinemia as a risk factor for vascular contributions to cognitive impairment and dementia. Front Aging Neurosci 2018; 10: 350-350
• 349 Crooks VC, Lubben J, Petitti DB, Little D, Chiu V. Social network, cognitive function, and dementia incidence among elderly women. Am J Public Health 2008; 98 (07) 1221-1227
• 350 Sutin AR, Stephan Y, Luchetti M, Terracciano A. Loneliness and risk of dementia. J Gerontol B Psychol Sci Soc Sci 2020; 75 (07) 1414-1422
• 351 Zebhauser A, Hofmann-Xu L, Baumert J. et al. How much does it hurt to be lonely? Mental and physical differences between older men and women in the KORA-Age Study. Int J Geriatr Psychiatry 2014; 29 (03) 245-252
• 352 Kuiper JS, Zuidersma M, Oude Voshaar RC. et al. Social relationships and risk of dementia: a systematic review and meta-analysis of longitudinal cohort studies. Ageing Res Rev 2015; 22: 39-57
• 353 Craig MC, Maki PM, Murphy DGM. The Women's Health Initiative Memory Study: findings and implications for treatment. Lancet Neurol 2005; 4 (03) 190-194
• 354 Yoo JE, Shin DW, Han K. et al. Female reproductive factors and the risk of dementia: a nationwide cohort study. Eur J Neurol 2020; 27 (08) 1448-1458
• 355 Rasgon NL, Geist CL, Kenna HA, Wroolie TE, Williams KE, Silverman DH. Prospective randomized trial to assess effects of continuing hormone therapy on cerebral function in postmenopausal women at risk for dementia. PLoS One 2014; 9 (03) e89095
• 356 Kato ET, Cannon CP, Blazing MA. et al. Efficacy and Safety of Adding Ezetimibe to Statin Therapy Among Women and Men: Insight From IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). J Am Heart Assoc 2017; 6 (11) 6
• 357 Chu CS, Tseng PT, Stubbs B. et al. Use of statins and the risk of dementia and mild cognitive impairment: A systematic review and meta-analysis. Sci Rep 2018; 8 (01) 5804
• 358 Seliger SL, Siscovick DS, Stehman-Breen CO. et al. Moderate renal impairment and risk of dementia among older adults: the Cardiovascular Health Cognition Study. J Am Soc Nephrol 2004; 15 (07) 1904-1911